Block‑Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125‑mediated immunosuppression is a research paper published in Oncology Letters (2021). On theSindex it has a DataRank of 0. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R03 CA241784
National Institutes of Health
Grant: 1R03CA241784-01A1
Next-generation anti-CD20 rituximab antibody that is engineered to be resistant to the immuno-suppressive effect mediated by the tumor-shed antigen, CA125
Fields of Study
Keywords
Sustainable Development Goals